BHP Early Infant Treatment Study

Phase 3, open-label trial of nevirapine, lopinavir + ritonavir, lamivudine and zidovudine in human immunodeficiency virus infection (HIV) (3 cohorts), sponsored by Harvard T.H. Chan School of Public Health. Primary endpoints: Proportion of infants who have treatment-limiting adverse events at 14 days, Proportion of infants who fail to achieve at least a 1.5 log10 copies/mL reduction in HIV-1 RNA at 14 days and 2 more. Started May 2015; status: active, not recruiting.